دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
New international reporting guidelines for clinical trials evaluating effectiveness of artificial intelligence interventions in dermatology: strengthening the SPIRIT of robust trial reporting
M. Charalambides C. Flohr P. Bahadoran R.N. Matin
doi : 10.1111/bjd.19616
Volume 184, Issue 3, March 2021, Pages: 381-383
What is new in the 2020 British guidelines for cutaneous squamous cell carcinoma?
U. Leiter
doi : 10.1111/bjd.19861
Volume 184, Issue 3, March 2021, Pages: 384-385
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of nonmelanoma skin cancer and accounts for 20% of all cutaneous malignancies. The incidence rate is increasing rapidly and may be associated with significant morbidity, especially in the elderly population.1, 2 Factors involved in the pathogenesis are exposure to ultraviolet radiation, age, male sex and immunosuppression.
Better reporting of safety data in clinical trials of biologic drugs in psoriasis is still needed
P. D?vila?Seijo
doi : 10.1111/bjd.19434
Volume 184, Issue 3, March 2021, Pages: 385
Tralokinumab for atopic dermatitis: a promising new therapy
D.E. Morra A.M. Drucker
doi : 10.1111/bjd.19699
Volume 184, Issue 3, March 2021, Pages: 386-387
What determines the treatment persistence in paediatric psoriasis?
A. Salman
doi : 10.1111/bjd.19436
Volume 184, Issue 3, March 2021, Pages: 387-388
Tight junctions in the skin: still a lot to learn
A. De Benedetto
doi : 10.1111/bjd.19390
Volume 184, Issue 3, March 2021, Pages: 388-389
Light in the dark: distinct effects of dimethyl fumarate on different T?cell subsets in psoriasis treatment
A. Mostafa T. Murata K. Kabashima
doi : 10.1111/bjd.19407
Volume 184, Issue 3, March 2021, Pages: 389-390
Co?occurrence of TERT promotor mutations with BRAF or NRAS alterations correlates with worse prognosis in melanoma
Y.?S. Sheen C.?Y. Chu
doi : 10.1111/bjd.19416
Volume 184, Issue 3, March 2021, Pages: 390-391
Early life regulation of inflammation in atopic dermatitis by microRNA
M.E. Polak
doi : 10.1111/bjd.19475
Volume 184, Issue 3, March 2021, Pages: 391-392
In this issue of the BJD, Nousbeck et al. explore the expression of microRNAs (miRNAs) in different blood compartments, and postulate their use as noninvasive biomarkers for paediatric eczema.
Treatment of hereditary palmoplantar keratoderma: a review by analysis of the literature
C. Bodemer P. Steijlen J. Mazereeuw?Hautier E.A. O'Toole
doi : 10.1111/bjd.19144
Volume 184, Issue 3, March 2021, Pages: 393-400
No specific or curative therapy exists for hereditary palmoplantar keratoderma (hPPK), which can profoundly alter patient quality of life, leading sometimes to severe functional impairment and pain. The rarity and the aetiological diversity of this group of disorders can explain the difficulty in comparing the efficacy of available treatments.
British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020
S.G. Keohane J. Botting P.G. Budny O.M. Dolan K. Fife C.A. Harwood R. Mallipeddi J.R. Marsden R.J. Motley C. Newlands C. Proby A. Rembielak D.N. Slater J.A. Smithson P. Buckley P. Fairbrother M. Hashme M.F. Mohd Mustapa L.S. Exton the British Association of Dermatologists’ Clinical Standards Unit
doi : 10.1111/bjd.19621
Volume 184, Issue 3, March 2021, Pages: 401-414
Meta?analysis results do not reflect the real safety of biologics in psoriasis
S. Afach A. Chaimani T. Evrenoglou L. Penso E. Brouste E. Sbidian L. Le Cleach
doi : 10.1111/bjd.19244
Volume 184, Issue 3, March 2021, Pages: 415-424
In reported systematic reviews and meta?analyses of randomized controlled trials (RCTs) assessing treatments for psoriasis, the proportion of serious adverse events (SAEs) did not differ between treatments and placebo. Including cases of psoriasis worsening as SAEs may explain the lack of difference.
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5?year results from the randomized placebo?controlled TRANSFIGURE study
K. Reich J. Sullivan P. Arenberger S. Jazayeri U. Mrowietz M. Augustin B. Elewski R. You P. Regnault J.A. Frueh
doi : 10.1111/bjd.19262
Volume 184, Issue 3, March 2021, Pages: 425-436
Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin?17A, a cornerstone cytokine in psoriasis, has shown long?lasting efficacy and safety in the complete spectrum of psoriasis manifestations.
Tralokinumab for moderate?to?severe atopic dermatitis: results from two 52?week, randomized, double?blind, multicentre, placebo?controlled phase III trials (ECZTRA 1 and ECZTRA 2)
A. Wollenberg A. Blauvelt E. Guttman?Yassky M. Worm C. Lynde J.?P. Lacour L. Spelman N. Katoh H. Saeki Y. Poulin A. Lesiak L. Kircik S.H. Cho P. Herranz M.J. Cork K. Peris L.A. Steffensen B. Bang A. Kuznetsova T.N. Jensen M.L. ?sterdal E.L. Simpson on behalf of the ECZTRA 1 and ECZTRA 2 study investigators
doi : 10.1111/bjd.19574
Volume 184, Issue 3, March 2021, Pages: 437-449
Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin?13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early and sustained improvements in AD signs and symptoms.
Tralokinumab plus topical corticosteroids for the treatment of moderate?to?severe atopic dermatitis: results from the double?blind, randomized, multicentre, placebo?controlled phase III ECZTRA 3 trial
J.I. Silverberg D. Toth T. Bieber A.F. Alexis B.E. Elewski A.E. Pink D. Hijnen T.N. Jensen B. Bang C.K. Olsen A. Kurbasic S. Weidinger on behalf of the ECZTRA 3 study investigators
doi : 10.1111/bjd.19573
Volume 184, Issue 3, March 2021, Pages: 450-463
Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin?13, a key driver of atopic dermatitis (AD).
Treatment persistence in paediatric and adolescent patients with psoriasis followed into young adulthood. From topical to systemic treatment: a prospective, longitudinal, observational cohort study of 448 patients
F.M. Bruins I.M.G.J. Bronckers R. Cai J.M.M. Groenewoud M. Krol E.M.G.J. de Jong M.M.B. Seyger
doi : 10.1111/bjd.19301
Volume 184, Issue 3, March 2021, Pages: 464-472
Although solely topical treatment often suffices, patients with psoriasis may require more intensive treatment (phototherapy and/or systemic treatments) to control their disease. However, in paediatric, adolescent and young adult patients, little is known about persistence of topical treatment and time until switch to systemic treatment.
Hyperhidrosis Quality of Life Index (HidroQoL©): further validation and clinical application in patients with axillary hyperhidrosis using data from a phase III randomized controlled trial
M. Gabes C. Jourdan K. Schramm C. Masur C. Abels P. Kamudoni S. Salek C. Apfelbacher
doi : 10.1111/bjd.19300
Volume 184, Issue 3, March 2021, Pages: 473-481
The Hyperhidrosis Quality of Life Index (HidroQoL©) is a validated patient?reported outcome measure capturing the quality of life of people affected by hyperhidrosis.
Organic osmolytes increase expression of specific tight junction proteins in skin and alter barrier function in keratinocytes
C. El?Chami A.R. Foster C. Johnson R.P. Clausen P. Cornwell I.S. Haslam M.C. Steward R.E.B. Watson H.S. Young C.A. O'Neill
doi : 10.1111/bjd.19162
Volume 184, Issue 3, March 2021, Pages: 482-494
The epidermal barrier is important for water conservation, failure of which is evident in dry?skin conditions. Barrier function is fulfilled by the stratum corneum, tight junctions (TJs, which control extracellular water) and keratinocyte mechanisms, such as organic osmolyte transport, which regulate intracellular water homeostasis. Organic osmolyte transport by keratinocytes is largely unexplored and nothing is known regarding how cellular and extracellular mechanisms of water conservation may interact.
Dimethyl fumarate modulates the Treg–Th17 cell axis in patients with psoriasis
J. Sulaimani D. Cluxton J. Clowry A. Petrasca O.E. Molloy B. Moran C.M. Sweeney A. Malara N. McNicholas C. McGuigan B. Kirby J.M. Fletcher
doi : 10.1111/bjd.19229
Volume 184, Issue 3, March 2021, Pages: 495-503
Dimethyl fumarate (DMF) is the active ingredient of Skilarence™ and Tecfidera™, which are used for the treatment of psoriasis and multiple sclerosis, respectively. Various immunomodulatory mechanisms of action have been identified for DMF; however, it is still unclear what effects DMF exerts in vivo in patients with psoriasis.
Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients
E. Manrique?Silva S. Rachakonda D. Mill?n?Esteban Z. Garc?a?Casado C. Requena V. Través R. Kumar E. Nagore
doi : 10.1111/bjd.19297
Volume 184, Issue 3, March 2021, Pages: 504-513
The distinct somatic mutations that define clinical and histopathological heterogeneity in cutaneous melanoma could be dependent on host susceptibility to exogenous factors like ultraviolet radiation.
MicroRNA analysis of childhood atopic dermatitis reveals a role for miR?451a
J. Nousbeck M.A. McAleer G. Hurault E. Kenny K. Harte S. Kezic R.J. Tanaka A.D. Irvine
doi : 10.1111/bjd.19254
Volume 184, Issue 3, March 2021, Pages: 514-523
MicroRNAs (miRNAs), important regulators of gene expression, have been implicated in a variety of disorders. The expression pattern of miRNAs in paediatric atopic dermatitis (AD) has not been well studied.
Should we be imaging lymph nodes at initial diagnosis of early?stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study
E. Hodak S. Sherman E. Papadavid M. Bagot C. Querfeld P. Quaglino H.M. Prince P.L. Ortiz?Romero R. Stadler R. Knobler E. Guenova T. Estrach A. Patsatsi Y.A. Leshem H. Prague?Naveh E. Berti S. Alberti?Violetti R. Cowan C. Jonak V. Nikolaou C. Mitteldorf O. Akilov L. Geskin R. Matin M. Beylot?Barry L. Vakeva J.A. Sanches O. Servitje S. Weatherhead M. Wobser J. Yoo M. Bayne A. Bates G. Dunnill M. Marschalko A.M. Buschots U. Wehkamp F. Evison E. Hong I. Amitay?Laish R. Stranzenbach M. Vermeer R. Willemze W. Kempf L. Cerroni S. Whittaker Y.H. Kim J.J. Scarisbrick on behalf of the Cutaneous Lymphoma International Consortium (CLIC) institutions
doi : 10.1111/bjd.19303
Volume 184, Issue 3, March 2021, Pages: 524-531
Early?stage mycosis fungoides (MF) includes involvement of dermatopathic lymph nodes (LNs) or early lymphomatous LNs. There is a lack of unanimity among current guidelines regarding the indications for initial staging imaging in early?stage presentation of MF in the absence of enlarged palpable LNs.
The challenging management of a series of 43 infants with Netherton syndrome: unexpected complications and novel mutations
N. Bellon S. Hadj?Rabia F. Moulin C. Lambe G. Lezmi F. Charbit?Henrion C. Alby L. Le Saché?de Peufeilhoux S. Leclerc?Mercier A. Hadchouel J. Steffann A. Hovnanian A. Lapillonne C. Bodemer
doi : 10.1111/bjd.19265
Volume 184, Issue 3, March 2021, Pages: 532-537
Netherton syndrome (NS) is a rare disease caused by SPINK5 mutations, featuring variable skin and hair involvement and, in many cases, allergic manifestations with a risk of lethality, particularly in infants. The clinical management of NS is challenging.
The effect of a dermato?oncological training programme on the diagnostic skills and quality of referrals for suspicious skin lesions by general practitioners
E. Marra M.C.J. van Rijsingen J.A.C. Alkemade J.M.M. Groenewoud K.F. Hueskes C.H.M. Nij Bijvank F.A. van de Laar S.F.K. Lubeek
doi : 10.1111/bjd.19214
Volume 184, Issue 3, March 2021, Pages: 538-544
The rising incidence rates of skin cancer (SC) lead to an enormous burden on healthcare systems. General practitioners (GPs) might play an important part in SC care, but research has shown poor clinical recognition of SC, leading to a high rate of potentially unnecessary referrals.
A call to standardize the BCC:SCC ratio
Z. Jiyad L. Marquart A.C. Green
doi : 10.1111/bjd.19550
Volume 184, Issue 3, March 2021, Pages: 545
The climate emergency: why should dermatologists care and how can they act?
M. Sun M. Rosenbach
doi : 10.1111/bjd.19610
Volume 184, Issue 3, March 2021, Pages: 546-547
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate?to?severe plaque psoriasis naïve to systemic treatment
A. Leutz A. Pinter D. Thaçi M. Augustin C. Schuster K. Fotiou H.P. Hundemer D. Saure U. Mrowietz K. Reich
doi : 10.1111/bjd.19558
Volume 184, Issue 3, March 2021, Pages: 548-550
Efficacy of topical ropivacaine in children and young adults with hereditary epidermolysis bullosa
E. Moreno Artero N. Schinkel S. Chaumon I. Corset T. Rabeony C. Elie N. Bellon C. Bodemer C. Greco
doi : 10.1111/bjd.19551
Volume 184, Issue 3, March 2021, Pages: 550-552
Effectiveness of clindamycin and rifampicin combination therapy in hidradenitis suppurativa: a 6?month prospective study
Y. Yao A.?H.R. J?rgensen H.C. Ring S.F. Thomsen
doi : 10.1111/bjd.19578
Volume 184, Issue 3, March 2021, Pages: 552-553
Investigating human eyelash hair follicle growth in situ and ex vivo: a pilot study
C.I. Platt J. Laybourne P. Cannon R. Paus
doi : 10.1111/bjd.19593
Volume 184, Issue 3, March 2021, Pages: 553-555
Antidrug antibodies to tumour necrosis factor inhibitors in hidradenitis suppurativa: a systematic review
J.D. Lu M. Milakovic V. Piguet A. Alavi
doi : 10.1111/bjd.19591
Volume 184, Issue 3, March 2021, Pages: 555-557
A qualitative exploration of the experiences of adolescents with alopecia areata and their messages for healthcare professionals
I. de Vere Hunt A. McNiven T. McPherson
doi : 10.1111/bjd.19598
Volume 184, Issue 3, March 2021, Pages: 557-559
Efficacy of in?class interleukin?23 inhibitor switching: risankizumab following guselkumab failure in moderate?to?severe psoriasis treatment
R. Reddy S. Pannu K. Fiumara J. Kahn D. Rosmarin
doi : 10.1111/bjd.19575
Volume 184, Issue 3, March 2021, Pages: 559-561
Long?term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients
E. Nettis G. Fabbrocini M. Ortoncelli G. Pellacani G. Argenziano E. Di Leo C. Patruno L. Stingeni C. Foti F. Rongioletti L. Macchia S. Tavecchio M. Napolitano S. Ribero L. Bonzano G. Calabrese D. Di Bona S.P. Nistic? K. Hansel P. Romita V. Piras M. Carbonara A. Detoraki S.M. Ferrucci
doi : 10.1111/bjd.19577
Volume 184, Issue 3, March 2021, Pages: 561-563
Motives for intentional sunlight exposure among young adult sexual minority men: appearance, relaxation and socialization in a cohort study
J.K. Robinson S. Wahood J.L. Stapleton
doi : 10.1111/bjd.19609
Volume 184, Issue 3, March 2021, Pages: 563-564
Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy
N. Haddad J. Delyon S. Trabelsi Messai F. Herms M.T. Leccia C. Lebbe J. Whitney S. Bhatia N. Basset?Seguin
doi : 10.1111/bjd.19604
Volume 184, Issue 3, March 2021, Pages: 564-566
Patient age and risk of recurrence of primary melanoma at high risk of spread
R. Ghiasvand K. Khosrotehrani M.C.B. Hughes L.A. von Schuckmann V.L. Beesley M. Malt B.M. Smithers A.C. Green
doi : 10.1111/bjd.19601
Volume 184, Issue 3, March 2021, Pages: 566-568
Exploring patient–physician trust dynamics in patients with psychocutaneous and general dermatological disease
P.?Z. Stavrou M.?A. Gkini R. Taylor A. Bewley
doi : 10.1111/bjd.19622
Volume 184, Issue 3, March 2021, Pages: 568-570
Hidradenitis suppurativa and perceived stigmatization in a diverse Canadian clinic population: a pilot study
D. Bouazzi M.L. McPhie R. Kj?rsgaard Andersen A. Alavi G.B.E. Jemec
doi : 10.1111/bjd.19626
Volume 184, Issue 3, March 2021, Pages: 570-571
Prevalence of allergic contact dermatitis to decyl and lauryl glucoside in the UK and Ireland
L.F. Soriano C.G. Bertram M.M.U. Chowdhury P. Cousen P. Divekar S.A. Ghaffar C. Green A. Havelin C.R. Holden G.A. Johnston A.A. Mughal E. Nic Dhonncha R.A. Sabroe N.M. Stone D.A. Thompson S.M. Wilkinson D.A. Buckley
doi : 10.1111/bjd.19603
Volume 184, Issue 3, March 2021, Pages: 571-573
Identifying the required degree of disease clearance to improve quality of life in pemphigus vulgaris
C.E. Bax A. Ravishankar D. Yan J. Concha C.J. Kushner D. Zamalin R. Feng A.S. Payne V.P. Werth
doi : 10.1111/bjd.19625
Volume 184, Issue 3, March 2021, Pages: 573-575
Occupational dermatoses during the COVID?19 pandemic: a multicentre audit in the UK and Ireland
H. O’Neill I. Narang D.A. Buckley T.A. Phillips C.G. Bertram T.O. Bleiker M.M.U. Chowdhury S.M. Cooper S. Abdul Ghaffar G.A. Johnston L.F. Kiely J.E. Sansom N. Stone D.A. Thompson P. Banerjee
doi : 10.1111/bjd.19632
Volume 184, Issue 3, March 2021, Pages: 575-577
Enhanced expression of angiotensin?converting enzyme 2 in psoriatic skin and its upregulation in keratinocytes by interferon??: implication of inflammatory milieu in skin tropism of SARS?CoV?2
M.K. Tembhre A.S. Parihar V.K. Sharma S. Imran N. Bhari R. Lakshmy A. Bhalla
doi : 10.1111/bjd.19670
Volume 184, Issue 3, March 2021, Pages: 577-579
A changed life: the life experiences of patients with psoriasis receiving biological treatment
T. Maruthappu A. Bewley
doi : 10.1111/bjd.19623
Volume 184, Issue 3, March 2021, Pages: 580
Response to ‘Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID?19 pandemic’
G. Murray D. Roche A. Ridge C. Hackett A.M. Tobin
doi : 10.1111/bjd.19667
Volume 184, Issue 3, March 2021, Pages: 580-581
The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice
E. Raschi M. La Placa E. Poluzzi F. De Ponti
doi : 10.1111/bjd.19677
Volume 184, Issue 3, March 2021, Pages: 581-583
Infantile bullous pemphigoid following serogroup B meningococcal vaccination
I. Navarro?Navarro D. Jiménez?Gallo S. Valenzuela?Ubi?a M. Dom?nguez?Gomez M. Linares?Barrios
doi : 10.1111/bjd.19480
Volume 184, Issue 3, March 2021, Pages: e53
Shades of grey: an outbreak of tattoo?associated Mycobacterium chelonae
A. Pararajasingam A. Atwan P. Srivastava M.M.U. Chowdhury N.M. Stone
doi : 10.1111/bjd.19487
Volume 184, Issue 3, March 2021, Pages: e54
Actinomycetoma caused by Nocardia asiatica associated with traditional Chinese medicine foot bath
Y. Ma C. Zhao R. Li X. Wang
doi : 10.1111/bjd.19566
Volume 184, Issue 3, March 2021, Pages: e55
Revolutionizing Atopic Dermatitis, 13–14 December 2020
doi : 10.1111/bjd.19722
Volume 184, Issue 3, March 2021, Pages: e56-e87
Analysis of small RNA molecules in childhood atopic dermatitis reveals a role for miR?451a
doi : 10.1111/bjd.19765
Volume 184, Issue 3, March 2021, Pages: e88
Atopic dermatitis (also known as atopic eczema) is the most common persistent inflammatory disease of early childhood, affecting more than 20% of children in developed countries. It causes extremely itchy skin and has a very significant impact on the quality of life of affected children and their families. It is caused by a combination of environmental factors and changes in the skin and immune system; however, the exact mechanisms behind the development of the disease are not fully understood.
A study into how the skin retains its moisture levels
doi : 10.1111/bjd.19766
Volume 184, Issue 3, March 2021, Pages: e89
Skin is a major physical barrier against water loss from within the body to the outside dry environment. A number of water?controlling structures are present in the skin, including the stratum corneum (the outer layer of the epidermis, which is the top layer of the skin) and the tight junctions (TJs). These are gasket?like seals composed of proteins that block the gaps between cells, therefore controlling water loss from outside of cells. The skin cells themselves contain water, which they can also lose. When this happens they can shrink. This is dangerous for the cells because if they shrink too much, they can die.
What’s the best treatment for inherited hard skin on the palms and soles?
doi : 10.1111/bjd.19767
Volume 184, Issue 3, March 2021, Pages: e90
Palmoplantar keratoderma (PPK) is a condition where the patient has thick, hard skin on the palms and soles. It can cause considerable discomfort and impairment of function. This problem is sometimes inherited (hPPK). There are many varieties of hPPK which are all uncommon. They show considerable variation in presentation, severity, genetics and associated abnormalities.
How do some genetic mutations affect the outcome of patients with skin melanoma?
doi : 10.1111/bjd.19768
Volume 184, Issue 3, March 2021, Pages: e91
The outcome for a type of skin cancer called melanoma can vary between different individuals. Apart from factors such as the depth of the tumour and degree of spread, the presence of markers for certain genetic changes (mutations) can also affect the disease outcome.
Treatment with secukinumab is highly effective in clearing nail psoriasis: long?term results from the TRANSFIGURE clinical trial
doi : 10.1111/bjd.19769
Volume 184, Issue 3, March 2021, Pages: e92
Psoriasis is a common skin disease that causes scaly patches on the skin, and can also affect the nails. Psoriasis affects a significant number of people throughout the world. The prevalence of nail symptoms in psoriasis ranges from less than 40% in patients with mild psoriasis to 50–70% in those with severe forms.
Improving skin cancer care with a general practitioner training programme
doi : 10.1111/bjd.19770
Volume 184, Issue 3, March 2021, Pages: e93
Skin cancer is the most common form of cancer in the world and the number of patients diagnosed with skin cancer is growing every year. Luckily, most patients with skin cancer can be treated and cured when diagnosed early.
Persistence of treatments in children with psoriasis followed into young adulthood: from topical to systemic treatments
doi : 10.1111/bjd.19771
Volume 184, Issue 3, March 2021, Pages: e94
Psoriasis is a common skin disease in both children and adults that causes scaly and itchy patches on the skin and may greatly reduce quality of life. It affects at least 100 million individuals worldwide.
Lessons from 43 infants with Netherton syndrome
doi : 10.1111/bjd.19772
Volume 184, Issue 3, March 2021, Pages: e95
Netherton syndrome is a genetic condition affecting about five people per million. It appears at or soon after birth with skin rash, unusual hair, allergy and abnormal immunity. Affected babies may become very ill, but severity varies and most dermatologists see only a few cases. Doctors from a specialist referral centre in Paris reviewed cases seen over 38 years to try to put together some guidelines.
New understanding of how treatment with dimethyl fumarate leads to improvements in psoriasis symptoms
doi : 10.1111/bjd.19773
Volume 184, Issue 3, March 2021, Pages: e96
Psoriasis is a chronic, inflammatory skin disease that affects approximately 2% of people. In the disease raised scaly plaques are found on the skin and this is driven by problems with the immune system.
Serious adverse events in trials evaluating biologics in psoriasis
doi : 10.1111/bjd.19774
Volume 184, Issue 3, March 2021, Pages: e97
Psoriasis is a common skin disease that causes itchy scaly patches, most frequently on the knees, elbows and scalp. It affects about 2–3% of people in the world. Patients with moderate?to?severe cases are often treated with drugs called biologics.
Should patients with early mycosis fungoides, a skin cancer of immune cells, undergo imaging to detect lymph node involvement?
doi : 10.1111/bjd.19775
Volume 184, Issue 3, March 2021, Pages: e98
Mycosis fungoides (MF) is a form of lymphoma, a cancer of immune cells called lymphocytes. In the early stages of MF only the skin is involved in the form of patches or plaques. In the later stages the skin is characterized by the appearance of nodules or generalized skin involvement, and the lymphoma may spread beyond the skin to involve primarily lymph nodes (glands) that become enlarged. In order to accurately assess the size and the structure of the lymph nodes imaging is needed.
Quality assessment of a quality?of?life questionnaire for patients with hyperhidrosis
doi : 10.1111/bjd.19776
Volume 184, Issue 3, March 2021, Pages: e99
Hyperhidrosis is a disease that causes excessive sweating. It affects around 1–2% of the world population and substantially impairs the quality of life of most people with the condition (for example because it results in limitations in daily activities, social relationships, study and work life).
Guidelines for the management of people with cutaneous squamous cell carcinoma
doi : 10.1111/bjd.19777
Volume 184, Issue 3, March 2021, Pages: e100
Primary cutaneous squamous cell carcinoma (cSCC) is a type of skin cancer. It is the sixth most common cancer in the UK and its incidence continues to rise. It has a 5% chance of spreading to other parts of the body.
Two identically designed studies to test the effectiveness of tralokinumab for treatment of atopic dermatitis in adults
doi : 10.1111/bjd.19778
Volume 184, Issue 3, March 2021, Pages: e101-e102
Atopic dermatitis, or eczema, is a chronic, itchy skin disease that is common in children and adults. Atopic dermatitis occurs when the barrier function of the skin is disrupted, allowing chemicals and allergens (that cause an allergic reaction) to enter the skin and cause inflammation.
Studying the effectiveness of the drug tralokinumab plus topical corticosteroids for the treatment of atopic dermatitis in adults
doi : 10.1111/bjd.19779
Volume 184, Issue 3, March 2021, Pages: e103-e104
Atopic dermatitis is a chronic disease that causes itchy skin and is the most common form of eczema. Atopic dermatitis is caused when the barrier function of the skin is disrupted, which allows allergens (that cause an allergic reaction) and chemicals to enter skin and cause inflammation.
?????????? RNA ??????? miR?451a ???
doi : 10.1111/bjd.19780
Volume 184, Issue 3, March 2021, Pages: e105
????? (????????) ???????????????, ?????? 20% ???????????????????, ???????????????????????????????????????????????; ??, ????????????????
???????????????
doi : 10.1111/bjd.19781
Volume 184, Issue 3, March 2021, Pages: e106
?????????????????????????????????????, ????? (????, ????????) ????? (TJ) ??????????????????, ??????????, ?????????????????????????, ???????????????????, ???????????????????, ??????????, ????????
????????????, ???????????
doi : 10.1111/bjd.19782
Volume 184, Issue 3, March 2021, Pages: e107
??????? (PPK) ???????????????????????????????????????????, ?????? (hPPK)?hPPK ????????, ?????????????????????????????????????
??????????????????????
doi : 10.1111/bjd.19783
Volume 184, Issue 3, March 2021, Pages: e108
?????????????????????????????????????, ?????? (??) ???????????????
??????????????????: TRANSFIGURE ?????????
doi : 10.1111/bjd.19784
Volume 184, Issue 3, March 2021, Pages: e109
?????????????, ????????????, ????????????????????????????????????????????? 40% ?????? 50–70% ???
?????????????????
doi : 10.1111/bjd.19785
Volume 184, Issue 3, March 2021, Pages: e110
???????????????, ?????????????????????????, ???????????????????
??????????????????: ??????????
doi : 10.1111/bjd.19786
Volume 184, Issue 3, March 2021, Pages: e111
????????????????, ??????????????, ??????????????????? 1 ??????
43 ? Netherton ??????????
doi : 10.1111/bjd.19787
Volume 184, Issue 3, March 2021, Pages: e112
Netherton ?????????, ??????????????????????????????????????????????????????, ???????, ???????????????????????????????38??????????, ?????????
???????????????????????
doi : 10.1111/bjd.19788
Volume 184, Issue 3, March 2021, Pages: e113
?????????????, ?? 2% ??????????, ??????????????, ?????????????
???????????????????????
doi : 10.1111/bjd.19789
Volume 184, Issue 3, March 2021, Pages: e114
???????????, ??????????, ?????????????? 2–3% ?????????????????????????????
??????? (????????) ????????????????????
doi : 10.1111/bjd.19790
Volume 184, Issue 3, March 2021, Pages: e115
????? (MF) ??????, ???????????????????? MF ????, ?????, ????????????????, ??????????????????, ??????????????, ????????? (??) ????????????????, ????????????????? MF ???????????, ??, ??????, ????????????????????????????, ???????????????????????????????? MF ?????????????????????????
??????????????????
doi : 10.1111/bjd.19791
Volume 184, Issue 3, March 2021, Pages: e116
?????????????????? 1?2% ???????, ?????????????????? (??, ?????????????????????????) ?
??????????????
doi : 10.1111/bjd.19792
Volume 184, Issue 3, March 2021, Pages: e117
?????????? (cSCC) ??????????????????, ??????????? 5% ??????????????
?????????, ???? tralokinumab ?????????????
doi : 10.1111/bjd.19793
Volume 184, Issue 3, March 2021, Pages: e118-e119
????????????????????, ????????????????????, ?????????? (?????????) ?????????, ??????????
???? tralokinumab ??????????????????????
doi : 10.1111/bjd.19794
Volume 184, Issue 3, March 2021, Pages: e120-e121
???????????????????, ??????????????????????, ????? (?????????) ??????????????, ??????????
